Tiger Aesthetics Medical has reorganized its commercial operations into two specialized divisions—BioBody for plastic surgery and BioDerma for dermatology and MedSpa—and is expanding its sales force to over 100 representatives by end of 2026. The move signals a strategic push to capture distinct channel segments in the medical aesthetics market, with a new product launch planned for early 2027.
Commercial restructuring details
The company has split its commercial organization into BioBody, targeting board-certified plastic and cosmetic surgeons, and BioDerma, focusing on dermatologists and medical spa providers. This dual-division structure is designed to provide tailored support and expand adoption of Tiger's adipose tissue-based products.
Sales force expansion and investment
Tiger Aesthetics is increasing investment in sales personnel, commercial programs, and operational infrastructure. The combined sales force is expected to exceed 100 representatives by the end of 2026, with further growth planned thereafter.
Product pipeline and timeline
The company currently markets alloClae, a structural adipose tissue product for breast and body contouring. It plans to launch dermaClae, targeting facial and hand rejuvenation, in early 2027. The new divisions are positioned to support both existing and upcoming products.
Leadership and channel strategy
Stephen Stafford will lead BioDerma, overseeing expansion into dermatology and MedSpa markets. "With alloClae growing rapidly and dermaClae on the horizon, we’re assembling a team and a commercial engine built specifically for all key channels in Medical Aesthetics," Stafford said. Tiger President Caro Van Hove noted the structure aims to provide more targeted support to healthcare providers while expanding commercial reach.
What buyers should watch
Distributors and clinic buyers should note Tiger Aesthetics' increasing segmentation of plastic surgery and dermatology channels, which may require separate sourcing and partnership strategies. The planned dermaClae launch in early 2027 and the growing sales force signal a push for broader market penetration in breast, facial, body contouring, and regenerative aesthetics.
Source: Read the original report | Published: June 17, 2026